Drug intelligence / Profile preview

E0302 SR2

Development stage: Unknown
Lead developer: Eisai
Modality: Drug Delivery Systems
Administration: Oral

Overview

E0302 SR2 is a sustained release (SR) tablet formulation containing the drug E0302. It has been evaluated in clinical trials, specifically pharmacokinetic (PK) and safety studies in healthy participants under fed conditions. These trials compared E0302 SR2 with other formulations, including E0302 SR1, E0302 SR3, and E0302 immediate release (IR) tablets. In at least one study, E0302 SR2 was administered as a single 1500 mcg dose.

Brand names: Rozebalamin
Other names: mecobalaminVitamin B12

Targets

MTR (Methionine synthase)

Beyond the preview

Go deeper on E0302 SR2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on E0302 SR2.

Explore the full profile